Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.
Ionis Pharmaceuticals, Inc. develops RNA-targeted medicines and reports news around marketed medicines and a pipeline in neurology, cardiometabolic disease and other high-need areas. Company updates commonly address commercial performance for TRYNGOLZA, financial results, R&D revenue from partnerships, and progress across antisense oligonucleotide programs.
Clinical and regulatory news also covers programs such as olezarsen for severe hypertriglyceridemia, zilganersen for Alexander disease, and partner-developed bepirovirsen for chronic hepatitis B. Governance and investor-relations releases include annual meeting materials, board composition changes, and healthcare conference presentations.
Ionis Pharmaceuticals (NASDAQ: IONS) will host a live webcast on July 14, 2020, at 10:00 a.m. Eastern Time to discuss its neurology franchise. The presentation will feature key executives, including CEO Brett P. Monia and Chief Scientific Officer Frank Bennett, covering various neurological diseases like Amyotrophic Lateral Sclerosis, Alzheimer's, Parkinson's, and more. Participants can access the webcast through Ionis' website, where a replay will also be available.
Ionis is recognized for its leadership in RNA-targeted therapeutics.
Akcea Therapeutics (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals (NASDAQ:IONS), will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 3:30 p.m. ET. CEO Damien McDevitt and CCO Kyle Jenne will represent the company in this virtual event. Participants can access the live webcast through Akcea's website.Akcea focuses on developing drugs for serious and rare diseases, including TEGSEDI and WAYLIVRA, leveraging Ionis' proprietary technology.